CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

Stashenko, 1980, Characterization of a human B lymphocyte-specific antigen, J Immunol, 125, 1678, 10.4049/jimmunol.125.4.1678 Tedder, 1994, CD20: a regulator of cell-cycle progression of B lymphocytes, Immunol Today, 15, 450, 10.1016/0167-5699(94)90276-3 Nadler, 1981, A unique cell surface antigen identifying lymphoid malignancies of B cell origin, J Clin Invest, 67, 134, 10.1172/JCI110005 Oettgen, 1983, Further biochemical studies of the human B-cell differentiation antigens B1 and B2, Hybridoma, 2, 17, 10.1089/hyb.1983.2.17 Ishibashi, 2001, Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor, Gene, 264, 87, 10.1016/S0378-1119(00)00598-9 Liang, 2001, Structural organization of the human MS4A gene cluster on chromosome 11q12, Immunogenetics, 53, 357, 10.1007/s002510100339 Tedder, 1988, Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes, Proc Natl Acad Sci U S A, 85, 208, 10.1073/pnas.85.1.208 Polyak, 1998, Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment, J Immunol, 161, 3242, 10.4049/jimmunol.161.7.3242 Ernst, 2005, Isolation and characterization of the B-cell marker CD20, Biochemistry, 44, 15150, 10.1021/bi0511078 Tedder, 1988, Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes, J Biol Chem, 263, 10009, 10.1016/S0021-9258(19)81618-6 Clark, 1989, Activation of human B cells, J Immunol, 143, 3873, 10.4049/jimmunol.143.12.3873 Teeling, 2006, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20, J Immunol, 177, 362, 10.4049/jimmunol.177.1.362 Polyak, 2002, Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure, Blood, 99, 3256, 10.1182/blood.V99.9.3256 Du, 2009, Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20, Mol Immunol, 46, 2419, 10.1016/j.molimm.2009.04.009 Du, 2007, Structural basis for recognition of CD20 by therapeutic antibody rituximab, J Biol Chem, 282, 15073, 10.1074/jbc.M701654200 Polyak, 2008, CD20 homo-oligomers physically associate with the B cell antigen receptor, J Biol Chem, 283, 18545, 10.1074/jbc.M800784200 Li, 2004, The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism, J Biol Chem, 279, 19893, 10.1074/jbc.M400525200 Polyak, 2003, A cholesterol-dependent CD20 epitope detected by the FMC7 antibody, Leukemia, 17, 1384, 10.1038/sj.leu.2402978 Szollosi, 1996, Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY, J Immunol, 157, 2939, 10.4049/jimmunol.157.7.2939 Leveille, 1999, CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines, Eur J Immunol, 29, 65, 10.1002/(SICI)1521-4141(199901)29:01<65::AID-IMMU65>3.0.CO;2-E Petrie, 2002, Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts, J Immunol, 169, 2886, 10.4049/jimmunol.169.6.2886 Walshe, 2008, Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling, J Biol Chem, 283, 16971, 10.1074/jbc.M708459200 O'Keefe, 1998, Mice carrying a CD20 gene disruption, Immunogenetics, 48, 125, 10.1007/s002510050412 Uchida, 2004, Mouse CD20 expression and function, Int Immunol, 16, 119, 10.1093/intimm/dxh009 Bubien, 1993, Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes, J Cell Biol, 121, 1121, 10.1083/jcb.121.5.1121 Kanzaki, 1995, Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells, J Biol Chem, 270, 13099, 10.1074/jbc.270.22.13099 Li, 2003, Store-operated cation entry mediated by CD20 in membrane rafts, J Biol Chem, 278, 42427, 10.1074/jbc.M308802200 Golay, 1985, The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle, J Immunol, 135, 3795, 10.4049/jimmunol.135.6.3795 Cragg, 2004, Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents, Blood, 103, 2738, 10.1182/blood-2003-06-2031 Deans, 1998, Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment, J Biol Chem, 273, 344, 10.1074/jbc.273.1.344 Lim, 2010, Anti-CD20 monoclonal antibodies—historical and future perspectives, Haematologica, 95, 135, 10.3324/haematol.2008.001628 Cragg, 2003, Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts, Blood, 101, 1045, 10.1182/blood-2002-06-1761 Chan, 2003, CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts, Cancer Res, 63, 5480 Ivanov, 2009, Homotypic adhesion and lysosome-mediated cell death evoked by anti-CD20 (tositumomab) and HLA DR monoclonal antibodies, J Clin Invest, 119 Ivanov, 2008, Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis, Clin Cancer Res, 14, 4925, 10.1158/1078-0432.CCR-07-5072 Glennie, 2007, Mechanisms of killing by anti-CD20 monoclonal antibodies, Mol Immunol, 44, 3823, 10.1016/j.molimm.2007.06.151 Umana, 2009 Ghetie, 2001, Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin, Blood, 97, 1392, 10.1182/blood.V97.5.1392 Goldenberg, 2009, Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody, Blood, 113, 1062, 10.1182/blood-2008-07-168146 Di Gaetano, 2003, Complement activation determines the therapeutic activity of rituximab in vivo, J Immunol, 171, 1581, 10.4049/jimmunol.171.3.1581 Golay, 2006, The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes, Haematologica, 91, 176 Hamaguchi, 2005, The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice, J Immunol, 174, 4389, 10.4049/jimmunol.174.7.4389 Minard-Colin, 2008, Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV, Blood, 112, 1205, 10.1182/blood-2008-01-135160 Uchida, 2004, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy, J Exp Med, 199, 1659, 10.1084/jem.20040119 Gong, 2005, Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy, J Immunol, 174, 817, 10.4049/jimmunol.174.2.817 Beers, 2008, Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation, Blood, 112, 4170, 10.1182/blood-2008-04-149161 Hamaguchi, 2006, Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy, J Exp Med, 203, 743, 10.1084/jem.20052283 Li, 2007, Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models, J Immunol, 179, 4263, 10.4049/jimmunol.179.6.4263 Racila, 2008, A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma, Clin Cancer Res, 14, 6697, 10.1158/1078-0432.CCR-08-0745 Wang, 2008, NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement, Blood, 111, 1456, 10.1182/blood-2007-02-074716 Wang, 2009, Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model, Blood, 114, 5322, 10.1182/blood-2009-01-200469 Jilani, 2003, Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia, Blood, 102, 3514, 10.1182/blood-2003-01-0055 Michel, 2002, Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells, Clin Cancer Res, 8, 2701 Press, 1987, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas, Blood, 69, 584, 10.1182/blood.V69.2.584.584 Cragg, 2004, Apparent modulation of CD20 by rituximab: an alternative explanation, Blood, 103, 3989, 10.1182/blood-2003-12-4384 Austin, 2004, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin, Mol Biol Cell, 15, 5268, 10.1091/mbc.E04-07-0591 Tefferi, 1996, Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia, Am J Clin Pathol, 106, 457, 10.1093/ajcp/106.4.457 Beum, 2006, The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes, J Immunol, 176, 2600, 10.4049/jimmunol.176.4.2600 Lin, 2003, Rituximab in B-cell chronic lymphocytic leukemia, Semin Oncol, 30, 483, 10.1016/S0093-7754(03)00239-2